PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

Abstract Background The favourable safety profile and the increasing confidence with immune checkpoint inhibitors (ICIs) might have boosted their prescription in frail patients with short life expectancies, who usually are not treated with standard chemotherapy. Methods The present analysis aims to...

Full description

Bibliographic Details
Main Authors: Daniele Santini, Tea Zeppola, Marco Russano, Fabrizio Citarella, Cecilia Anesi, Sebastiano Buti, Marco Tucci, Alessandro Russo, Maria Chiara Sergi, Vincenzo Adamo, Luigia S. Stucci, Melissa Bersanelli, Giulia Mazzaschi, Francesco Spagnolo, Francesca Rastelli, Francesca Chiara Giorgi, Raffaele Giusti, Marco Filetti, Paolo Marchetti, Andrea Botticelli, Alain Gelibter, Marco Siringo, Marco Ferrari, Riccardo Marconcini, Maria Giuseppa Vitale, Linda Nicolardi, Rita Chiari, Michele Ghidini, Olga Nigro, Francesco Grossi, Michele De Tursi, Pietro Di Marino, Laura Pala, Paola Queirolo, Sergio Bracarda, Serena Macrini, Stefania Gori, Alessandro Inno, Federica Zoratto, Enrica T. Tanda, Domenico Mallardo, Maria Grazia Vitale, Thomas Talbot, Paolo A. Ascierto, David J. Pinato, Corrado Ficorella, Giampiero Porzio, Alessio Cortellini
Format: Article
Language:English
Published: BMC 2021-06-01
Series:Journal of Translational Medicine
Subjects:
Immunotherapy
Immune checkpoint inhibitors
End-of-life
Palliative care
Appropriateness
Online Access:https://doi.org/10.1186/s12967-021-02937-9

Internet

https://doi.org/10.1186/s12967-021-02937-9

Similar Items